|Day Low/High||63.07 / 64.81|
|52 Wk Low/High||62.66 / 100.23|
Elliott's previous successes in the healthcare space bode well for its chances at athena.
The drug is responsible for more than 60% of AbbVie's top line.
Jim Cramer is bullish on AbbVie, Broadcom, Enbridge Energy Partners, and Commercial Vehicle Group.
Jim Cramer says investors are migrating toward sectors likely to have the biggest upside in the second half.
Stocks move mostly lower on Thursday after the House passes a bill to repeal and replace the Affordable Care Act.
Cramer shares his views on which is better: Amazon or Alphabet, and discusses the domino effect when oil falls.
Jim Cramer says this market is strong enough to withstand falling oil prices and a tax plan that will face a lot of obstacles.
A guide to keep track of all the companies reporting first quarter financial results today -- making sense of what's important and disregarding what's not.
Stocks hold onto slight to modest gains Thursday afternoon after positive earnings help to offset a slump in crude oil prices and a decline in energy names.
Stocks turn mixed on Thursday after a slump in crude oil prices, and a decline in energy names, snarl earlier upward momentum.
Stock futures creep higher on Thursday as Wall Street returns its attention to positive earnings for market direction after a day focused on the White House's tax reform plans.
U.S. stock futures rise modestly Thursday after Donald Trump's tax plan fails to deliver any surprises but instead raises many more questions.
Nobody shows their hand in negotiations. Why should government? This new tax plan must go to Congress.
Biotech investors should keep a close eye on the progress in this huge potential market.
The New Brunswick, N.J.-based company noted that its pharma sales dipped due to weakness in the U.S. compared to other markets.
Full-steam ahead for earnings season in the coming week as a range of industry leaders across a swath of sectors release their recent quarterly performances.
Jim Cramer is bullish on EQT Midstream Partners, AbbVie, Blackstone Group, and Core Civic.
Jim Cramer looks at how the French elections are smacking the U.S stock markets. Plus, he has the week-ahead game plan for oil and stocks.
The FDA action was a win for Pfizer because Xeljanz escapes competition for one year or more.
Gilead, Pfizer, Abbvie stand to gain from Lilly and Incyte Rheumatoid Arthritis Setback.
The pharmaceutical giant has an attractive yield supported by double-digit earnings growth.
The maker of the EpiPen seems incapable of overcoming its troubles.
It's pretty normal to have profit-taking after such a strong first quarter.
Subscribers to Dividend Stock Advisor will now receive Income Seeker, our newest premium product.
Sign up to get started or log in to see your watchlist.
Enter a symbol above to add it to your watchlist.
A confirmation email has been sent to the address provided during registration. Please click on the appropriate link to confirm your email address.